US FDA’s Opaque Galafold Review: A Rare Misstep In The Trump Era
Executive Summary
When FDA reversed course and allowed Amicus to file for Accelerated Approval of migalastat, plenty of people suspected politics were at play. The agency's handling of the review won’t do anything to allay those suspicions.
You may also be interested in...
Will A US FDA Advisory Committee Be In Intercept's Future?
There are strong reasons to justify an advisory committee meeting for the NASH application, but also an outlet for the US FDA to skip it.
Keeping Track: Poteligeo, Onpattro, Galafold And Annovera Approved; Selinexor Submitted
The latest drug development news and highlights from our US FDA Performance Tracker.
FDA Reversal Gives Amicus Renewed Hope For US Oral Fabry Launch
Amicus plans to file migalastat for Fabry disease in the US in the fourth quarter, after FDA gave the greenlight, reversing a decision last year to require an additional Phase III study. Additional information includes European submission data and post-launch RWE.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: